Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) major shareholder Skorpios Trust sold 1,937,500 shares of the firm’s stock in a transaction dated Thursday, September 19th. The stock was sold at an average price of $14.05, for a total value of $27,221,875.00. Following the transaction, the insider now directly owns 8,906,181 shares in the company, valued at approximately $125,131,843.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
Stoke Therapeutics Price Performance
NASDAQ STOK traded down $0.48 on Monday, hitting $13.27. 600,519 shares of the company’s stock were exchanged, compared to its average volume of 808,356. The firm’s 50-day moving average price is $14.50 and its two-hundred day moving average price is $13.21. The firm has a market cap of $691.65 million, a price-to-earnings ratio of -5.51 and a beta of 0.96. Stoke Therapeutics, Inc. has a fifty-two week low of $3.35 and a fifty-two week high of $17.58.
Stoke Therapeutics (NASDAQ:STOK – Get Free Report) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.11. The business had revenue of $4.83 million for the quarter, compared to analyst estimates of $3.33 million. Stoke Therapeutics had a negative return on equity of 57.89% and a negative net margin of 683.35%. On average, research analysts predict that Stoke Therapeutics, Inc. will post -2.18 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Stoke Therapeutics
Analyst Ratings Changes
Several equities analysts recently issued reports on the company. Wedbush restated an “outperform” rating and issued a $17.00 price target on shares of Stoke Therapeutics in a research report on Thursday, July 11th. HC Wainwright restated a “buy” rating and issued a $35.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, September 11th. Finally, Needham & Company LLC restated a “buy” rating and issued a $22.00 price target on shares of Stoke Therapeutics in a research report on Thursday, August 8th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $21.40.
Check Out Our Latest Report on Stoke Therapeutics
About Stoke Therapeutics
Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.
Recommended Stories
- Five stocks we like better than Stoke Therapeutics
- Where to Find Earnings Call Transcripts
- The Average 401k Balance by Age Explained
- 3 Ways To Invest In Coffee, Other Than Drinking It
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- Top Stocks Investing in 5G Technology
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.